Published in Cardiovasc Res on February 16, 2001
Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood (2006) 8.56
Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest (2002) 4.38
The immune system and cardiac repair. Pharmacol Res (2008) 3.42
The serum response factor coactivator myocardin is required for vascular smooth muscle development. Proc Natl Acad Sci U S A (2003) 3.40
Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood (2005) 2.91
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol (2014) 2.86
Engineering complex tissues. Tissue Eng (2006) 2.53
Design, fabrication and implementation of a novel multi-parameter control microfluidic platform for three-dimensional cell culture and real-time imaging. Lab Chip (2008) 2.34
Functional muscle regeneration with combined delivery of angiogenesis and myogenesis factors. Proc Natl Acad Sci U S A (2009) 2.29
Chloride intracellular channel-4 is a determinant of native collateral formation in skeletal muscle and brain. Circ Res (2009) 2.02
VE-statin, an endothelial repressor of smooth muscle cell migration. EMBO J (2003) 1.84
TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. Blood (2008) 1.83
Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF. Proc Natl Acad Sci U S A (2006) 1.66
Peritubular capillary loss after mouse acute nephrotoxicity correlates with down-regulation of vascular endothelial growth factor-A and hypoxia-inducible factor-1 alpha. Am J Pathol (2003) 1.63
Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell (2007) 1.61
Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos. Blood (2008) 1.47
In vitro modeling of the neurovascular environment by coculturing adult human brain endothelial cells with human neural stem cells. PLoS One (2014) 1.45
Sustained expression of homeobox D10 inhibits angiogenesis. Am J Pathol (2002) 1.44
HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B (2015) 1.40
Targeting angiogenesis: structural characterization and biological properties of a de novo engineered VEGF mimicking peptide. Proc Natl Acad Sci U S A (2005) 1.38
Brugia malayi Asparaginyl - tRNA Synthetase Stimulates Endothelial Cell Proliferation, Vasodilation and Angiogenesis. PLoS One (2016) 1.37
Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer. Neoplasia (2009) 1.34
Adenosine A(2A) receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis. Am J Pathol (2004) 1.33
Survivin-dependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced up-regulation. Am J Pathol (2003) 1.29
Formation of composite endothelial cell-mesenchymal stem cell islets: a novel approach to promote islet revascularization. Diabetes (2008) 1.26
Preventing local regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 enhances angiogenesis. Proc Natl Acad Sci U S A (2005) 1.26
Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice. Proc Natl Acad Sci U S A (2003) 1.26
Recruitment and activation of phospholipase Cgamma1 by vascular endothelial growth factor receptor-2 are required for tubulogenesis and differentiation of endothelial cells. J Biol Chem (2003) 1.26
Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli. Am J Pathol (2003) 1.24
Cell therapy of hip osteonecrosis with autologous bone marrow grafting. Indian J Orthop (2009) 1.22
Characterization of vascular mural cells during zebrafish development. Mech Dev (2009) 1.21
Mechanical overload induces VEGF in cartilage discs via hypoxia-inducible factor. Am J Pathol (2004) 1.18
Endothelial colony-forming cells from preterm infants are increased and more susceptible to hyperoxia. Am J Respir Crit Care Med (2009) 1.17
Role of endothelial progenitor cells during ischemia-induced vasculogenesis and collateral formation. Microvasc Res (2010) 1.16
reg6 is required for branching morphogenesis during blood vessel regeneration in zebrafish caudal fins. Dev Biol (2003) 1.14
Enhancing microvascular formation and vessel maturation through temporal control over multiple pro-angiogenic and pro-maturation factors. Biomaterials (2013) 1.14
Molecular ecophysiology of Antarctic notothenioid fishes. Philos Trans R Soc Lond B Biol Sci (2007) 1.13
EGFL7 meets miRNA-126: an angiogenesis alliance. J Angiogenes Res (2010) 1.12
Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age. Review of 50 consecutive patients aged 1 day-60 years. Neuroradiology (2005) 1.10
Netrin-4 induces lymphangiogenesis in vivo. Blood (2010) 1.10
Rasip1 is required for endothelial cell motility, angiogenesis and vessel formation. Dev Biol (2009) 1.10
Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig (2009) 1.09
Sequential delivery of immunomodulatory cytokines to facilitate the M1-to-M2 transition of macrophages and enhance vascularization of bone scaffolds. Biomaterials (2014) 1.06
HIF-1alpha: a valid therapeutic target for tumor therapy. Cancer Res Treat (2004) 1.06
Adeno-associated viral vector-mediated hypoxia-regulated VEGF gene transfer promotes angiogenesis following focal cerebral ischemia in mice. Gene Ther (2007) 1.05
Targeting angiogenesis to restore the microcirculation after reperfused MI. Nat Rev Cardiol (2009) 1.05
Nitrite anion therapy protects against chronic ischemic tissue injury in db/db diabetic mice in a NO/VEGF-dependent manner. Diabetes (2013) 1.04
Lymphatic vessels arise from specialized angioblasts within a venous niche. Nature (2015) 1.04
Dynamic regulation of the cerebral cavernous malformation pathway controls vascular stability and growth. Dev Cell (2012) 1.04
Temporal profile of Src, SSeCKS, and angiogenic factors after focal cerebral ischemia: correlations with angiogenesis and cerebral edema. Neurochem Int (2011) 1.02
Hypoxia-inducible factor-1alpha and -2alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1alpha is associated with prognosis. Br J Cancer (2009) 1.02
Partial persistence of exercise-induced myocardial angiogenesis following 4-week detraining in the rat. Histochem Cell Biol (2008) 1.01
Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases. Curr Drug Targets (2013) 1.01
A review of metabolic staging in severely injured patients. Scand J Trauma Resusc Emerg Med (2010) 1.01
Reactive oxygen species promote angiogenesis in the infarcted rat heart. Int J Exp Pathol (2009) 1.01
Micropatterned three-dimensional hydrogel system to study human endothelial-mesenchymal stem cell interactions. J Tissue Eng Regen Med (2010) 1.00
Endoglin plays distinct roles in vascular smooth muscle cell recruitment and regulation of arteriovenous identity during angiogenesis. Dev Dyn (2009) 0.98
Low level laser therapy increases angiogenesis in a model of ischemic skin flap in rats mediated by VEGF, HIF-1α and MMP-2. J Photochem Photobiol B (2013) 0.98
Antiangiogenic therapies for advanced hepatocellular carcinoma. Oncologist (2013) 0.94
HoxA5 stabilizes adherens junctions via increased Akt1. Cell Adh Migr (2007) 0.93
Pericytes at the intersection between tissue regeneration and pathology. Clin Sci (Lond) (2015) 0.92
Cerebral microvascular rarefaction induced by whole brain radiation is reversible by systemic hypoxia in mice. Am J Physiol Heart Circ Physiol (2010) 0.92
Current and future treatments for hepatocellular carcinoma. World J Gastroenterol (2015) 0.92
Perivascular cells in blood vessel regeneration. Biotechnol J (2013) 0.91
Functional characterization of embryonic stem cell-derived endothelial cells. J Vasc Res (2011) 0.91
Endothelial colony-forming cell conditioned media promote angiogenesis in vitro and prevent pulmonary hypertension in experimental bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol (2013) 0.91
Whole brain radiation-induced impairments in learning and memory are time-sensitive and reversible by systemic hypoxia. PLoS One (2012) 0.91
AAV-mediated gene transfer of human pigment epithelium-derived factor inhibits Lewis lung carcinoma growth in mice. Oncol Rep (2012) 0.90
Imbalances in serum angiopoietin concentrations are early predictors of septic shock development in patients with post chemotherapy febrile neutropenia. BMC Infect Dis (2010) 0.90
The para-aortic ridge plays a key role in the formation of the renal, adrenal and gonadal vascular systems. J Anat (2010) 0.89
Ritonavir inhibits HIF-1α-mediated VEGF expression in retinal pigment epithelial cells in vitro. Eye (Lond) (2013) 0.89
Therapeutic Effects of Acupuncture through Enhancement of Functional Angiogenesis and Granulogenesis in Rat Wound Healing. Evid Based Complement Alternat Med (2012) 0.89
Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapy. World J Gastrointest Surg (2010) 0.89
Bisphosphonates' antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay. Clin Oral Investig (2013) 0.89
Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies. Biomed Res Int (2015) 0.89
Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model. Br J Cancer (2011) 0.88
Angiogenic sprouting is regulated by endothelial cell expression of Slug. J Cell Sci (2014) 0.88
The epidermal growth factor-like domain of CD93 is a potent angiogenic factor. PLoS One (2012) 0.88
Regenerative medicine: Current therapies and future directions. Proc Natl Acad Sci U S A (2015) 0.86
Blood-brain barrier breakdown and neovascularization processes after stroke and traumatic brain injury. Curr Opin Neurol (2015) 0.86
Human tears reveal insights into corneal neovascularization. PLoS One (2012) 0.86
Developmental and pathological angiogenesis in the central nervous system. Cell Mol Life Sci (2014) 0.86
Control of blood vessel identity: from embryo to adult. Ann Vasc Dis (2008) 0.86
Characterization of vascular endothelial growth factor receptors on the endothelial cell surface during hypoxia using whole cell binding arrays. Anal Biochem (2007) 0.86
Exocyst-mediated membrane trafficking is required for branch outgrowth in Drosophila tracheal terminal cells. Dev Biol (2014) 0.86
Restoration of blood flow by using continuous perimuscular infiltration of plasmid DNA encoding subterranean mole rat Spalax ehrenbergi VEGF. Proc Natl Acad Sci U S A (2003) 0.85
Wnt1 is a proangiogenic molecule, enhances human endothelial progenitor function, and increases blood flow to ischemic limbs in a HGF-dependent manner. FASEB J (2011) 0.85
Potentiation of angiogenic switch in capillary endothelial cells by cAMP: A cross-talk between up-regulated LLO biosynthesis and the HSP-70 expression. Glycoconj J (2006) 0.85
Polarisation of T-cadherin to the leading edge of migrating vascular cells in vitro: a function in vascular cell motility? Histochem Cell Biol (2003) 0.85
Angiogenesis and lymphangiogenesis as prognostic factors after therapy in patients with cervical cancer. Contemp Oncol (Pozn) (2012) 0.85
Endothelial cells regulate cardiomyocyte development from embryonic stem cells. J Cell Biochem (2010) 0.85
Vascular endothelial growth factor (VEGF) fails to improve blood flow and to promote collateralization in a diabetic mouse ischemic hindlimb model. Cardiovasc Diabetol (2003) 0.84
O2 level controls hematopoietic circulating progenitor cells differentiation into endothelial or smooth muscle cells. PLoS One (2009) 0.84
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl) (2015) 0.84
Anti-angiogenic properties of a sulindac analogue. Br J Pharmacol (2007) 0.83
Cystathionine γ-lyase regulates arteriogenesis through NO-dependent monocyte recruitment. Cardiovasc Res (2015) 0.83
Imaging tumor angiogenesis. J Clin Invest (2006) 0.83
Utility of co-transplanting mesenchymal stem cells in islet transplantation. World J Gastroenterol (2011) 0.83
Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain. J Bone Miner Res (2016) 0.83
Dissecting the role of endothelial SURVIVIN DeltaEx3 in angiogenesis. Blood (2006) 0.82
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 18.47
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature (1998) 11.61
Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell (1999) 7.33
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med (2001) 6.73
In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med (2001) 5.54
The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med (2001) 5.28
Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature (1983) 5.27
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med (1999) 4.85
Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet (2001) 4.66
Physiological consequences of loss of plasminogen activator gene function in mice. Nature (1994) 4.40
Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med (1999) 4.33
Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem (1982) 3.95
On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost (1980) 3.44
Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet (1997) 3.40
Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. Gene (1999) 3.00
Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost (2006) 2.81
Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem (1981) 2.80
Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med (2001) 2.66
Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol (1999) 2.56
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med (1998) 2.54
Role of tissue factor in embryonic blood vessel development. Nature (1996) 2.54
Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol (2000) 2.53
Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost (2003) 2.49
Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome. Nat Med (2001) 2.46
Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood (2000) 2.44
Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc Natl Acad Sci U S A (2001) 2.42
Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation (1995) 2.38
Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation (1998) 2.32
Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest (1993) 2.20
Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest (1998) 2.19
VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med (2000) 2.13
Transcription factor hepatocyte nuclear factor 6 regulates pancreatic endocrine cell differentiation and controls expression of the proendocrine gene ngn3. Mol Cell Biol (2000) 2.11
Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest (1993) 2.08
Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol (2001) 2.06
Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost (1981) 1.98
Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest (1985) 1.97
Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation (1999) 1.97
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol (2001) 1.94
A novel role for VEGF in endocardial cushion formation and its potential contribution to congenital heart defects. Development (2001) 1.92
Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation (1997) 1.91
PR39, a peptide regulator of angiogenesis. Nat Med (2000) 1.90
Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol (2001) 1.89
On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem (1978) 1.86
Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood (1998) 1.81
Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem (1988) 1.77
Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene. Circ Res (2002) 1.73
Molecular mechanism of physiological fibrinolysis. Nature (1978) 1.71
On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen. Biochim Biophys Acta (1979) 1.69
Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood (1988) 1.68
Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci U S A (1996) 1.66
Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem (1976) 1.66
Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol (2000) 1.64
Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet (1985) 1.60
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med (1991) 1.58
Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med (1984) 1.57
Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. J Biol Chem (1980) 1.56
On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. J Thromb Haemost (2005) 1.55
Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest (1998) 1.55
Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. J Clin Invest (2005) 1.55
Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation (1986) 1.55
Mice lacking the gene encoding tissue-type plasminogen activator show a selective interference with late-phase long-term potentiation in both Schaffer collateral and mossy fiber pathways. Proc Natl Acad Sci U S A (1996) 1.54
Generation and characterization of urokinase receptor-deficient mice. J Clin Invest (1996) 1.54
Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice. J Thromb Haemost (2005) 1.53
Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol (1990) 1.51
Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature (1997) 1.50
Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol (1998) 1.48
Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase. Circulation (1995) 1.47
Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res (1984) 1.46
Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature (1981) 1.45
Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1). J Thromb Haemost (2004) 1.45
Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis. Circulation (1990) 1.45
Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost (1987) 1.44
Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. Circulation (1991) 1.44
Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest (1997) 1.44
A mouse model for Zellweger syndrome. Nat Genet (1997) 1.43
The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer (2008) 1.41
Intravascular coagulation in liver disease. Annu Rev Med (1974) 1.40
Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am J Pathol (1997) 1.40
Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann N Y Acad Sci (2000) 1.40